Q & A column, 11/14

Create PDF

1. Lombarts AJ, de Kieviet W. Recognition and prevention of pseudothrombocytopenia and concomitant pseudoleukocytosis. Am J Clin Pathol. 1988;89:634–639.
2. Gulati GL, Asselta A, Chen C. Using a vortex to disaggregate platelet clumps. Laboratory Medicine. 1997;28:665–667.
3. Perrotta G, Roberts L, Glazier J, Schumacher HR. Use of sodium citrate anticoagulant for routine hematology analysis on the CELL-DYN® 4000: an opportunity to enhance efficiency in the clinical laboratory. Laboratory Hematology. 1998;4:156–162.

Kyle T. Bradley, MD, MS, Assistant Professor, Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Member, CAP Hematology/Clinical Microscopy Resource Committee

[hr]

Q. What are the regulations for corrective action for nucleated red blood cells? How many NRBCs per high-powered field are required to meet criteria to do the mathematical equation to correct the NRBCs? Also, what is the mathematical equation for correcting NRBCs? Do you have a sample policy on correcting NRBCs and an accompanying equation?

A. Clinical laboratories are required to have a procedure for identifying interfering substances and altering test reports accordingly. CAP checklist requirement HEM.30100 (hematology and coagulation checklist, 2014 edition) specifies that a laboratory must have in place a procedure for detecting and correcting automated white blood cell counts for the presence of NRBCs and megakaryocytes. NRBC values are commonly expressed in proportionate terms as number of NRBCs per 100 WBCs. The corrected WBC count using this NRBC value is equal to the total nucleated cell count multiplied by (100/[100 + NRBCs]). Alternatively, absolute values may be derived simply by multiplying the proportion of each cell type including NRBCs by the total nucleated cell count. Expression of WBC differential results in absolute count units (×109/L) is preferred since values are not subject to the inherent problems interpreting relative percentage values.

There is no universally accepted standard level of NRBCs at which WBC count correction must occur. It is up to the laboratory director to establish acceptable limits in consultation with the medical staff; threshold values that trigger a correction of the WBC count should be no higher than is deemed clinically significant. Though the presence of even one or two NRBCs per 100 WBCs may have significant clinical importance, not correcting the WBC count when NRBCs make up less than five percent of total nucleated cells and reporting a proportionately false high WBC count is not likely to have an impact on clinical decision-making. Some laboratories correct the WBC count for any number of measured NRBCs. The impact of NRBCs on leukocyte differential values should also be considered and corrected because many instruments may classify them erroneously as lymphocytes and report false lymphocytosis or miss reporting significant lymphopenia.

There is a great deal of vendor and model differences in automated CBC instruments that determine reliability and manner in which spurious results are detected and what cell types are potentially interfered with. Users should know the details of their instrument’s performance and limitations. Newer instruments are capable of quantifying one percent or more NRBCs—often below levels reliably detected using microscopic-based methods—and automatically report only the corrected cell counts.

1. de Keijzer MH, van der Meer W. Automated counting of nucleated red blood cells in blood samples of newborns. Clin Lab Haematol. 2002;24:243–245.
2. Kwon MJ, Nam MH, Kim SH, et al. Evaluation of the nucleated red blood cell count in neonates using the Beckman Coulter UniCel DxH 800 analyzer. Int J Lab Hematol. 2011;33:620–628.
3. Zandecki M, Genevieve F, Gérard J, Godon A. Spurious counts and spurious results on hematology analyzers: white blood cells, red blood cells, hemoglobin, red cell indices, and reticulocytes. In: Kottke-Marchant K, Davis BH, eds. Laboratory Hematology Practice. Hoboken, NJ: Wiley-Blackwell/International Society for Laboratory Hematology; 2012:75–95.

David L. Zwick, MD, Director, Hematology Laboratory, Children’s Mercy Hospital and Clinics, Kansas City, Mo., Former member, CAP Hematology/Clinical Microscopy Resource Committee

Dr. Kiechle is medical director of clini­cal pathology, Memorial Healthcare, Hollywood, Fla. Use the reader service card to submit your inquiries, or address them to Sherrie Rice, CAP TODAY, 325 Wau­ke­gan Road, Northfield, IL 60093; srice@cap.org.